Merck & Co Says FDA Approves Pembrolizumab With Chemotherapy For Primary Advanced Or Recurrent Endometrial Carcinoma; Recommended Pembrolizumab Dose Is 200mg Every 3 Weeks Or 400mg Every 6 Weeks Until Disease Progression Unacceptable Toxicity Or Up To 24 Months
Portfolio Pulse from Benzinga Newsdesk
Merck & Co announced that the FDA has approved the use of Pembrolizumab in combination with chemotherapy for the treatment of primary advanced or recurrent endometrial carcinoma.
June 17, 2024 | 4:32 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Merck & Co received FDA approval for Pembrolizumab in combination with chemotherapy for treating primary advanced or recurrent endometrial carcinoma. This approval could potentially increase the company's revenue and market share in the oncology sector.
FDA approval of a new treatment typically leads to increased sales and market share for the company. Pembrolizumab is a significant product in Merck's oncology portfolio, and this approval expands its use, likely boosting revenue.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100